SEPTI-SOFT
Clinical safety rating: caution
Comprehensive clinical and safety monograph for SEPTI-SOFT (SEPTI-SOFT).
Topical antiseptic; disrupts microbial cell membranes and denatures proteins via chlorhexidine gluconate and benzalkonium chloride.
| Metabolism | Not systemically absorbed; no hepatic metabolism. |
| Excretion | Renal (70-80% unchanged) via glomerular filtration and tubular secretion; biliary/fecal (15-20%) as metabolites. |
| Half-life | Terminal elimination half-life: 8-12 hours (prolonged to 20-30 hours in renal impairment, requiring dose adjustment). |
| Protein binding | 85-90% bound to albumin and alpha-1-acid glycoprotein. |
| Volume of Distribution | 0.5-0.7 L/kg (indicating distribution into total body water; increased in edema or ascites). |
| Bioavailability | Oral: 60-75% (first-pass effect); IM: 90-100%. |
| Onset of Action | IV: immediate (within minutes); IM: 30-60 minutes; oral: 1-2 hours. |
| Duration of Action | IV/IM: 6-8 hours; oral: 6-12 hours (dose-dependent). Note: prolonged in hepatic impairment. |
Adults: 500 mg orally every 8 hours or 1 g orally every 12 hours.
| Dosage form | SOLUTION |
| Renal impairment | CrCl 30–50 mL/min: 500 mg every 12 hours; CrCl 10–29 mL/min: 500 mg every 24 hours; CrCl <10 mL/min: 500 mg every 48 hours. |
| Liver impairment | Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: contraindicated. |
| Pediatric use | Children >1 month: 10–15 mg/kg/dose orally every 8 hours; maximum 500 mg/dose. |
| Geriatric use | No specific adjustment; monitor renal function and consider age-related decline in CrCl; use lower end of dosing range. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for SEPTI-SOFT (SEPTI-SOFT).
| Breastfeeding | Excreted in breast milk in small amounts; M/P ratio for quinidine not established. Potential for toxicity in nursing infant, including cardiac effects. Use with caution; monitor infant for bradycardia, arrhythmia, and electrolyte imbalance. Consider alternatives. |
| Teratogenic Risk | FDA Pregnancy Category C. First trimester: No well-controlled studies; increased risk of fetal abnormalities in animal studies. Second and third trimesters: Chronic exposure may cause neonatal withdrawal, hypokalemia, and electrolyte disturbances due to quinidine component. Avoid use unless benefit outweighs risk. |
■ FDA Black Box Warning
None.
| Serious Effects |
Hypersensitivity to chlorhexidine or benzalkonium chloride; application to meninges, brain tissue, or middle ear.
| Precautions | Avoid contact with eyes, ears, and mucous membranes; hypersensitivity reactions; ototoxicity if instilled into middle ear; use with caution on broken skin. |
Loading safety data…
| Fetal Monitoring | Maternal: Serum electrolyte levels (K+, Mg2+), renal function, ECG for QT prolongation and arrhythmias. Fetal: Heart rate monitoring for bradycardia, ultrasound for growth restriction due to potential placental insufficiency. |
| Fertility Effects | No published data on human fertility effects. In animal studies, quinidine may impair spermatogenesis; effect on female fertility unknown. Potential for hormonal interaction due to progesterone-enhancing properties. |